Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Articles

Phase I and Clinical Pharmacological Evaluation of Pirozantrone Hydrochloride (Oxantrazole)

Matthew M. Ames, Charles L. Loprinzi, Jerry M. Collins, Carol van Haelst-Pisani, Ronald L. Richardson, Joseph Rubin and Charles G. Moertel
Matthew M. Ames
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles L. Loprinzi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerry M. Collins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol van Haelst-Pisani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald L. Richardson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Rubin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles G. Moertel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published July 1990
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Pirozantrone hydrochloride, an anthrapyrazole analogue, was selected for clinical evaluation based on broad antitumor activity against murine tumor systems and on potentially less cardiotoxicity when compared to anthracyclines. This anthrapyrazole analogue is currently under clinical evaluation, and we now report results on a Phase I clinical trial incorporating a pharmacologically guided dose-escalation scheme. Dose escalation was designed to proceed by factors of 2 until the patient drug exposure (concentration × time) was 40% of the murine exposure at the LD10 dose (90 mg/m2). Thereafter, more moderate dose escalations were employed. The target concentration × time value (59 µg-min/ml) derived from preclinical pharmacology data was exceeded in all three patients at a dose of 90 mg/m2. A dose of 160 mg/m2 was found to reproducibly result in appropriate myelosuppression. This dose is recommended for further testing in Phase II studies. Nonhematological toxicities encountered in this trial were mild, the most notable being phlebitis at the infusion site. Objective responses were observed in two patients, one with metastatic breast cancer and another with metastatic melanoma. Following a 60-min infusion, pirozantrone hydrochloride plasma elimination was monoexponential, with a half-life of approximately 30 min, mean total body clearance of 1.29 liters/min/m2, and mean steady state volume of distribution of 29 liters/m2.

Footnotes

  • ↵1 This work was supported in part by National Cancer Institute Contract CM 57733, DHHS.

  • ↵2 To whom requests for reprints should be addressed, at Department of Oncology, Mayo Clinic & Foundation, 200 First Street S. W., Rochester, MN 55905.

  • ↵3 Office of Research Resources, Food and Drug Administration, Parklawn 13B21, Rockville, MD, 20857.

  • Received December 18, 1989.
  • Revision received March 6, 1990.
  • ©1990 American Association for Cancer Research.
PreviousNext
Back to top
July 1990
Volume 50, Issue 13
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Phase I and Clinical Pharmacological Evaluation of Pirozantrone Hydrochloride (Oxantrazole)
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Phase I and Clinical Pharmacological Evaluation of Pirozantrone Hydrochloride (Oxantrazole)
Matthew M. Ames, Charles L. Loprinzi, Jerry M. Collins, Carol van Haelst-Pisani, Ronald L. Richardson, Joseph Rubin and Charles G. Moertel
Cancer Res July 1 1990 (50) (13) 3905-3909;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Phase I and Clinical Pharmacological Evaluation of Pirozantrone Hydrochloride (Oxantrazole)
Matthew M. Ames, Charles L. Loprinzi, Jerry M. Collins, Carol van Haelst-Pisani, Ronald L. Richardson, Joseph Rubin and Charles G. Moertel
Cancer Res July 1 1990 (50) (13) 3905-3909;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Genetic Control of Programmed Cell Death in the Nematode Caenorhabditis elegans
  • Tissue Structure, Nuclear Organization, and Gene Expression in Normal and Malignant Breast
  • The Prizes
Show more Articles
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement